Biointron x Chinese Antibody Society Webinar: RushData: Delivering Rapid Wet-Lab Data to Close the Loop on AI-Designed Antibodies

When

July 4, 2026, 9:00 PM ET

Register now >>

About

The antibody therapeutics sector is rapidly evolving, transitioning from traditional hybridoma methods to single B and AI-driven de novo design approaches, significantly compressing discovery timelines and creating novel binding moieties. To capitalize on this shift, as the leading CRO in antibody discovery, Biointron has introduced integrated service packages featuring rapid expression(1 day) and ultra-fast characterization (in 10 days). These offerings are specifically engineered to accelerate the Design-Build-Test-Learn (DBTL) cycle of AIDD companies, enabling data-driven optimizations on molecules and algorithms. Furthermore, Biointron is fortifying their infrastructure through automation and digital intelligence while enhancing capabilities to deliver challenging modalities including multi-specific antibodies and ADCs. This strategic evolution ensures Biointron meet diverse client demands, providing end-to-end solutions that bridge computational design with robust, high-throughput experimental execution.

Register now >>

About the Speaker

Brady Wu, PhD, Head of Protein Center at Biointron

Dr. Brady Wu is a multidisciplinary scientist and biotech leader. He holds a Ph.D. in Chemistry from The Ohio State University (2007–2013), where he pioneered solid-state NMR studies of amyloid fibril dynamics, and a Peking University honors B.S. in Biology (2003–2007). At GenScript (2013–2021), he led 100+ teams in recombinant protein production service and global project management. As the Founding CEO of Solvo Biotherapeutics (2022–2024), he built China’s top cell-free protein synthesis platform with a 15+ team. Now leading the Protein Science group at Biointron (2024–present), he drives ADC conjugation, developability assessment, and recombinant protein/antibody R&D efforts in the company.

Register now >>